690 reports of this reaction
4.7% of all PEGVALIASE PQPZ reports
#3 most reported adverse reaction
INJECTION SITE ERYTHEMA is the #3 most commonly reported adverse reaction for PEGVALIASE PQPZ, manufactured by BioMarin Pharmaceutical Inc.. There are 690 FDA adverse event reports linking PEGVALIASE PQPZ to INJECTION SITE ERYTHEMA. This represents approximately 4.7% of all 14,737 adverse event reports for this drug.
Patients taking PEGVALIASE PQPZ who experience injection site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE ERYTHEMA is moderately reported among PEGVALIASE PQPZ users, representing a notable but not dominant share of adverse events.
In addition to injection site erythema, the following adverse reactions have been reported for PEGVALIASE PQPZ:
The following drugs have also been linked to injection site erythema in FDA adverse event reports:
INJECTION SITE ERYTHEMA has been reported as an adverse event in 690 FDA reports for PEGVALIASE PQPZ. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE ERYTHEMA accounts for approximately 4.7% of all adverse event reports for PEGVALIASE PQPZ, making it one of the most commonly reported side effect.
If you experience injection site erythema while taking PEGVALIASE PQPZ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.